全文获取类型
收费全文 | 894篇 |
免费 | 72篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 20篇 |
儿科学 | 26篇 |
妇产科学 | 17篇 |
基础医学 | 91篇 |
口腔科学 | 27篇 |
临床医学 | 106篇 |
内科学 | 98篇 |
皮肤病学 | 16篇 |
神经病学 | 148篇 |
特种医学 | 65篇 |
外科学 | 98篇 |
综合类 | 48篇 |
预防医学 | 64篇 |
眼科学 | 15篇 |
药学 | 84篇 |
1篇 | |
肿瘤学 | 43篇 |
出版年
2022年 | 6篇 |
2021年 | 17篇 |
2020年 | 14篇 |
2019年 | 18篇 |
2018年 | 10篇 |
2017年 | 13篇 |
2016年 | 11篇 |
2015年 | 16篇 |
2014年 | 25篇 |
2013年 | 52篇 |
2012年 | 46篇 |
2011年 | 38篇 |
2010年 | 28篇 |
2009年 | 15篇 |
2008年 | 39篇 |
2007年 | 30篇 |
2006年 | 33篇 |
2005年 | 30篇 |
2004年 | 29篇 |
2003年 | 30篇 |
2002年 | 27篇 |
2001年 | 15篇 |
2000年 | 24篇 |
1999年 | 24篇 |
1998年 | 22篇 |
1997年 | 22篇 |
1996年 | 18篇 |
1995年 | 14篇 |
1994年 | 17篇 |
1993年 | 14篇 |
1992年 | 12篇 |
1991年 | 15篇 |
1990年 | 15篇 |
1989年 | 20篇 |
1988年 | 11篇 |
1987年 | 17篇 |
1986年 | 15篇 |
1985年 | 13篇 |
1984年 | 9篇 |
1983年 | 5篇 |
1982年 | 5篇 |
1979年 | 6篇 |
1977年 | 7篇 |
1975年 | 6篇 |
1974年 | 11篇 |
1973年 | 8篇 |
1969年 | 7篇 |
1968年 | 7篇 |
1967年 | 6篇 |
1966年 | 11篇 |
排序方式: 共有967条查询结果,搜索用时 15 毫秒
41.
Engeland C Mahoney C Mohr E Ilivitsky V Knott VJ 《Pharmacology, biochemistry, and behavior》2002,72(1-2):457-464
The auditory mismatch negativity (MMN) event-related brain potential (ERP) reflects the storage of information in acoustic sensory memory. Thirteen patients with Alzheimer's disease (AD), 6 receiving treatment with the cholinesterase inhibitor, tacrine [tetrahydroaminoacridine (THA)], and 7 receiving no treatment, were administered 2 mg of nicotine polacrilex and placebo. MMNs were recorded with 1- and 3-s interstimulus intervals (ISIs) during pre- and post-placebo/nicotine administration. Amplitudes decreased from pre- to post-placebo recordings in nontreated patients but remained stable in THA-treated patients. Comparison of pre- and post-nicotine MMNs found amplitude increases with nicotine in nontreated but not in THA-treated patients. MMN latencies were shortened by nicotine in both treatment groups. These exploratory findings suggest that nicotine-improved strength of acoustic sensory memory traces and speed of acoustic sensory discrimination in AD are differentially affected by chronic tacrine treatment. 相似文献
42.
Lawrence S Engel Nathaniel Rothman Charles Knott Charles F Lynch Nyla Logsden-Sackett Robert E Tarone Michael C Alavanja 《Cancer epidemiology, biomarkers & prevention》2002,11(5):493-496
Epidemiological studies are increasingly collecting buccal cells and other sources of DNA for genetic analysis. However, high refusal rates raise concerns about possible selection bias. This study examines the subject characteristics associated with refusal or failure to provide a buccal cell sample. Subjects were male farmers in the Agricultural Health Study, which is being conducted in Iowa and North Carolina. As part of a 5-year follow-up, cohort members were contacted by telephone and asked to participate in a telephone interview and to consent to providing a buccal cell sample using a kit that was mailed to them. Demographic, lifestyle, disease, and occupational characteristics were compared between consenters who returned a sample ("compliers"), nonconsenters ("refusers"), and consenters who failed to return a sample ("noncompliers"). Compliers (n = 8794), refusers (n = 3178), and noncompliers (n = 3008) were quite similar, although compliers tended to be slightly older. Although some significant differences between these groups were observed, the magnitude of these differences was generally small, usually no more than a few percentage points. In conclusion, this study found little difference between male farmers who agreed to provide buccal cell samples versus those who either refused to provide a sample or who agreed but failed to return the sample. Observed differences were typically small and would be unlikely to compromise etiologic associations identified in such a prospective study. In short, there appears to be little selection bias in the Agricultural Health Study buccal cell collection process, further supporting the use of such mailed collection kits in epidemiological research. 相似文献
43.
Gutman S Bernhardt P Pinkos A Moxey-Mims M Knott T Cooper J 《Diabetes technology & therapeutics》2002,4(6):779-781
The Medical Device Amendments of 1976 to the Federal Food, Drug, and Cosmetic Act (the Act) established three regulatory classes for medical devices. Section 513 of the Act specifies three classes based upon the degree of control and Food and Drug Administration (FDA) oversight that is necessary to assure that the various types of devices are safe and effective. High-risk devices are placed into the most regulated device class, Class III. Under Section 515 of the Act, all devices placed in Class III are subject to premarket approval (PMA) requirements. PMA by FDA is the required process of scientific review to ensure the safety and effectiveness of Class III devices. Advisory panel review is required of virtually all original submissions. Manufacturing facilities of devices requiring PMA approval are also subject to preapproval inspection to assure data integrity and compliance with good manufacturing practices. An approved PMA is granted for marketing a particular medical device for a particular intended use. FDA considers noninvasive and minimally invasive glucose devices that are intended to measure, monitor, or predict blood glucose levels in diabetics to be high-risk medical devices. These devices will have a significant potential impact on the medical care of people with diabetes. The technology offers potential improvements in the quality of life, enhanced blood glucose control through increased frequency of testing, or access to testing, in a broader range of patients. However, the technology is not yet well understood, and the information obtained from these devices is often different from the information that has been the traditional base for the management of diabetes. As a result, FDA requires both analytical and clinical studies to support the intended claims for these new devices. 相似文献
44.
45.
Cytogenetic and molecular genetic analysis of tumorigenic human bronchial epithelial cells induced by radon alpha particles 总被引:4,自引:1,他引:4
To establish a cell culture model for lung carcinogenesis, independent
populations of the human papillomavirus 18-immortalized human bronchial
epithelial cell line BEP2D were treated with high linear energy transfer
radon-simulated alpha-particles, expanded and xenotransplanted into Nu/Nu
mice. Six independent cell lines were established from tumors that
developed from three separate radiation treatments as follows: treatment
(Tx) 1 (30 cGy--two doses), H2BT, Tx 2 (30 cGy-- single dose), R30T1L,
R30T2 and R30T3L, Tx 3 (30 cGy--single dose), H1ATN and H1ATBA1.
Cytogenetic analysis revealed common changes in all tumor lines: loss of
the Y chromosome (ch), one of three copies of ch8, one of three copies of
ch14, and one of two copies of ch4p16-pter and ch11p15-pter. Analysis of
polymerase chain reaction-amplified short tandem repeats of informative
loci confirmed the loss of chY in all lines and loss of heterozygosity
(LOH) at eight loci spanning the length of ch8 in all lines from Tx's 1 and
2. Our data support previous studies indicating the presence of tumor
suppressor genes on ch8. LOH also was confirmed on ch14 at locus D14S306 in
all cell lines from Tx 2 and in one of two lines from Tx 3. This region,
14q12-q13, may contain changes in one of the five known somatostatin
receptor genes (SSTR1). No LOH was detected at any of the informative loci
tested for on ch4 or ch11.
相似文献
46.
Two distinct tumor cell growth-inhibiting factors from a human rhabdomyosarcoma cell line 总被引:8,自引:0,他引:8
Tumor cell growth-inhibiting factors (TIFs) have been shown to inhibit the growth of tumor cell lines in culture. TIF-1, the first TIF to be described, is a low-molecular-weight, acid- and heat-stable polypeptide with no antiviral activity. A second class of TIFs (TIF-2) has now been isolated from the conditioned media of a human rhabdomyosarcoma cell line and partially purified by polyacrylamide gel filtration, cation exchange, and reverse-phase high-pressure liquid chromatography. Partially purified preparations of TIF-2 inhibit the growth of a variety of human tumor cells in soft agar and monolayer cultures and are mitogenic for normal human and mouse cells. TIF-2 has no antiviral activity. The growth-inhibitory effects of TIF-2 are reversible when the affected cells are no longer exposed to the factor. Although both TIF-1 and TIF-2 are obtained from the same source, they can be distinguished by their molecular weight, heat lability, elution pattern from reverse-phase high-pressure liquid chromatography, and their effect on the growth of mink lung epithelial cells. The growth of a human tumor cell variant, selected for resistance to growth inhibition by TIF-1, is inhibited by TIF-2. TIFs may therefore be a family of related polypeptides which selectively inhibit the growth of tumor cells. 相似文献
47.
Hemophilia B (Christmas disease) is a rare, X-linked bleeding diathesis, which may present with life-threatening hemorrhage. Management of the coagulopathy in the setting of free tissue transfer may be particularly challenging. The authors present the first case in the English literature of a male with hemophilia B undergoing microvascular free flap reconstruction, as well as a review of the current surgical and medical management of hemophilia B. Based upon this experience, perioperative specific factor replacement is recommended. Given physiologic trough levels of the replaced factor, routine antiplatelet therapy appears appropriate. Management of free tissue transfer in the setting of severe hemophilia is significantly more challenging and should benefit from multidisciplinary coordination. 相似文献
48.
49.
50.